Table 2b.
Endopoints OS
| OS |
Univariate analysis |
Multivariate analysis |
||||
|---|---|---|---|---|---|---|
| Variable | HR | 95% CI | P | HR | 95% CI | P |
| Age at diagnosis | ||||||
| >45 | 3.30 | 1.33-8.23 | 0.010 | 4.65 | 1.65-13.09 | 0.004 |
| Sex | ||||||
| Male | 1.09 | 0.44-2.69 | 0.848 | |||
| ENSAT stage at diagnosis | ||||||
| III-IV | 1.54 | 0.64-3.72 | 0.339 | |||
| Hormone hypersecretion | ||||||
| Yes | 2.69 | 1.14-6.34 | 0.024 | 3.45 | 1.35-8.79 | 0.009 |
| Proliferation index (Ki67) | 1.02 | 0.99-1.06 | 0.254 | |||
| Surgery of primary tumor | ||||||
| No | 1.94 | 0.44-8.63 | 0.384 | |||
| ECOG performance status at cabACC start | ||||||
| ≥1 | 1.11 | 0.43-2.86 | 0.825 | |||
| Charlson’s comorbidity index at cabACC start | ||||||
| >6 | 1.68 | 0.64-4.44 | 0.293 | |||
| Metastases lung at cabACC start | ||||||
| Yes | 1.28 | 0.51-3.26 | 0.600 | |||
| Metastases liver at cabACC start | ||||||
| Yes | 2.07 | 0.80-5.31 | 0.132 | |||
| ≥2 metastatic sites at cabACC start | ||||||
| Yes | 1.33 | 0.58-3.05 | 0.504 | |||
| Prior chemotherapy lines (before cabACC) | ||||||
| Less than 2 lines | 1.03 | 0.46-2.32 | 0.939 | |||
| LDH at cabACC start | ||||||
| Upper limit of normal | 4.42 | 1.60-12.21 | 0.004 | 5.12 | 1.70-15.37 | 0.004 |
| Albumin at cabACC start | ||||||
| Under limit of normal | 10.20 | 2.24-46.41 | 0.003 | |||
| Neutrophil-to-lymphocyte ratio (NLR) at cabACC start | ||||||
| ≥5 | 6.20 | 1.70-22.69 | 0.006 | |||
| Hemoglobin (Hb) at cabACC start | ||||||
| <12/13 g/dl (female/male) | 1.60 | 0.66-3.89 | 0.302 | |||
| BMI | ||||||
| < Median(23.4) | 1.13 | 0.50-2.55 | 0.772 | |||
| Mitotane blood level | ||||||
| ≥14 mg/l | 1.21 | 0.47-3.07 | 0.686 | |||
BMI, body mass index; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio, LDH, lactate dehydrogenase; ENSAT, European Network for the Study of Adrenal Tumors OS, overall survival; PFS, progression-free survival.
Bold indicates statistically significant P-values.